Sorafenib is metabolised primarily in the liver and undergoes oxidative metabolism, mediated by CYP 3A4, as well as glucuronidation mediated by UGT1A9.
Sorafeniib metaboliseerub peamiselt maksas, läbides oksüdatiivse metabolismi, mida vahendab CYP3A4, samuti glükuronidatsiooni teel, mida vahendab UGT1A9.